Log In Get Started
Press Releases April 14, 2026 04:15 PM

KRONOS WORLDWIDE, INC. ANNOUNCES EXPECTED FIRST QUARTER 2026 EARNINGS RELEASE DATE

Kronos Worldwide schedules first quarter 2026 earnings release for May 6, 2026

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
KRO

Kronos Worldwide, Inc., a leading global producer of titanium dioxide products, announced its expected earnings release date for the first quarter of 2026 as May 6, 2026, following market close, pending quarter-end closing procedures.

KRONOS WORLDWIDE, INC. ANNOUNCES EXPECTED FIRST QUARTER 2026 EARNINGS RELEASE DATE
KRO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Kronos Worldwide is a major international producer of titanium dioxide products.
  • The company plans to release its Q1 2026 earnings report on May 6, 2026, after market close.
  • Announcement reflects routine earnings reporting with no additional financial details provided.

DALLAS, TEXAS, April 14, 2026 (GLOBE NEWSWIRE) -- Kronos Worldwide, Inc. (NYSE: KRO) announced today that, subject to the completion of quarter-end closing procedures, it expects to report first quarter 2026 earnings in a press release after market close on Wednesday, May 6, 2026. 

Kronos Worldwide, Inc. is a major international producer of titanium dioxide products.

* * * * *

Investor Relations Contact

Bryan A. Hanley
Senior Vice President and Treasurer
Tel. 972-233-1700


Risks

  • Potential risks related to operational and market conditions impacting titanium dioxide demand and pricing.
  • Uncertainty regarding the forthcoming earnings results could influence market sentiment.
  • Economic factors affecting the chemicals and materials sector may pose risks to company performance.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026